好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Atypical Neoplastic Infiltration in the Cerebellum with Imaging and Clinical Findings Mimicking Cerebellitis
Neuro-oncology
Neuro-oncology Posters (7:00 AM-5:00 PM)
039

To report an atypical case of Acute Lymphoblastic Leukemia (ALL) with central nervous system (CNS) involvement recurrence with clinical and radiological findings mimicking cerebellitis

The specific mechanism of involvement of the CNS by acute leukemic cells is incompletely understood. CNS involvement in ALL are known to involve meninges, subarachnoid space and rarely, brain parenchyma, mimicking other CNS pathologies such as cerebellitis; which tends to be a self-limited condition treated with corticosteroid therapy for symptomatic relief. However, in contrast to cerebellitis, ALL with CNS involvement is not self-limited and requires other medical interventions such as chemotherapy or radiation.

We report the case of a 47 y/o Hispanic male patient with history of  ALL  with previous CNS involvement  in remission that  presented to Emergency Department due to acute onset occipital headache, nausea, vomiting, poor coordination, vertigo and imbalance. Physical examination was remarkable for dysmetria, dysdiadochokinesia and horizontal nystagmus. No fever, nuchal rigidity or decreased alertness. Workup including basic labs and CSF studies ruled out infectious etiology. Brain MRI was remarkable for diffuse abnormal signal intensity of cerebellum and bilateral, symmetrical cerebellar swelling suggestive of an acute cerebellitis. No pachymeningeal, parenchymal or leptomeningeal enhancement upon contrast administration were identified, making CNS malignancy less likely based on radiographic findings. CSF analysis including cytology and flow cytometry confirmed presence of malignant cells compatible with ALL recurrence with CNS involvement.

NA

Here we present a patient with recurrence of ALL in the CNS with clinical and imaging findings mimicking cerebellitis secondary to cerebellar infiltration. With this case we emphasize the importance of screening for neoplastic recurrence within the CNS in a patient with history of ALL and new neurological symptoms, to avoid delay in treatment and prevent further neurological decline. 

 

Authors/Disclosures
Raymond M. Rivera Vergara, MD
PRESENTER
Dr. Rivera Vergara has nothing to disclose.
Melissa A. Morales Garcia, MD Dr. Morales Garcia has nothing to disclose.
Karylane Palermo-Cruz, MD (University of Puerto Rico) Dr. Palermo-Cruz has nothing to disclose.
Daniel M. Reyes De Jesus, MD (UPR-Neurology Training Program) Dr. Reyes De Jesus has nothing to disclose.
Johnny A. Sanabria Lopez, MD Dr. Sanabria Lopez has nothing to disclose.
Jessica Abreu Garcia, MD Dr. Abreu Garcia has nothing to disclose.
No disclosure on file
No disclosure on file
David Blas-Boria, MD, FAAN (University of Puerto Rico) Dr. Blas-Boria has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novocure.
Franchesca Fiorito Torres, MD (University of PR) Dr. Fiorito Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Fiorito Torres has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Fiorito Torres has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli-Lilly. Dr. Fiorito Torres has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biohaven. Dr. Fiorito Torres has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie/Allergan. Dr. Fiorito Torres has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Fiorito Torres has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis.